Pulmonary Drugs Market Report 2026

Pulmonary Drugs Market Overview

• Pulmonary Drugs market size has reached to $56.98 billion in 2025 • Expected to grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden • Market Trend: Verona Pharma’s Ohtuvayre™ Approval Marks First Novel COPD Therapy in Over Two Decades • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Drugs Market?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses. The main drug class of pulmonary drugs is inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers to manage chronic respiratory conditions like asthma and COPD by reducing airway inflammation and preventing flare-ups. The various indications include asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others and they are distributed through several channels such as retail pharmacies, online pharmacies, and hospital pharmacies.

What Is The Pulmonary Drugs Market Growth Forecast?

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population growth, expansion of biologic pulmonary drugs, precision respiratory medicine adoption, increasing smoking-related disorders, improved access to inhaled therapies. Major trends in the forecast period include rising adoption of targeted respiratory therapies, growth of combination inhalation treatments, increasing focus on long-term disease control, expansion of biologic-based pulmonary drugs, shift toward personalized respiratory care.

What Is The Driver Of The Pulmonary Drugs Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the pulmonary drugs market going forward. Respiratory disorders refer to medical conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange. Respiratory disorders are increasing due to the growing prevalence of smoking, leading to lung damage and chronic diseases. Pulmonary drugs play a crucial role in managing respiratory disorders by improving lung function, reducing inflammation, and relieving airway obstruction for better breathing. For instance, in May 2025, according to the Centers for Disease Control and Prevention, a US-based government agency reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the rising respiratory diseases are driving the growth of the pulmonary drugs industry.

Key Players In The Global Pulmonary Drugs Market

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Global Pulmonary Drugs Market Trends and Insights

Major companies operating in the pulmonary drugs market are focusing on therapeutic innovation, such as dual PDE3 and PDE4 inhibition via inhaled delivery, to combine bronchodilator and non-steroidal anti-inflammatory effects in a single molecule for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Dual PDE3 and PDE4 inhibition enables simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, showing clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

What Are Latest Mergers And Acquisitions In The Pulmonary Drugs Market?

In September 2024, Roivant Sciences Ltd., a US-based biotechnology company, acquired medicine for pulmonary hypertension manufactured by Bayer AG for an undisclosed amount. With this acquisition, Roivant aims to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, enhancing patient outcomes and addressing unmet medical needs. Bayer AG is a Germany-based company that manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

What Defines the Pulmonary Drugs Market?

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmonary Drugs Market Report 2026?

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.